News Stories

LBBAP limits hospital readmissions after TAVR

LBBAP is associated with better long-term outcomes than traditional right ventricular pacing (RVP) when patients require a permanent pacemaker after TAVR, according to new findings published in Heart Rhythm

FDA approves Boston Scientific leads for left bundle branch area pacing

Boston Scientific has received U.S. Food and Drug Administration (FDA) approval for its Ingevity+ pacing leads to be used for left bundle branch area pacing (LBBAP) when connected to a single- or dual-chamber pacemaker.

FDA approves Biotronik lead, catheter for left bundle branch area pacing

Biotronik has received U.S. Food and Drug Administration (FDA) approval to make its Solia S lead and Selectra 3D catheter available for a new indication: left bundle branch area pacing (LBBAP).

Biotronik receives CE mark for Amvia Sky and Edge devices

Biotronik announced today the latest addition to its cardiac rhythm management portfolio.

FDA clears new drug-eluting envelope for implantable cardiac devices—CEO sees it as ‘tip of the iceberg’